MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted ...

MADISON, Wis. -- Abbott expects to close its acquisition of Exact Sciences on Monday, the healthcare giant said. Madison-based Exact Sciences is known for its cancer detection technology such as ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It was Bloomberg that first reported rumors of the buyout on Wednesday, citing that talks were nearing fruition, according to people familiar with the matter. At the time of the article, Exact only ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbott Laboratories ABT3.49%increase; up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences in a deal valued at about $21 billion, as Abbott looks to compete in the ...

Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. This marks one of Abbott's largest deals ...

In an article published that morning and updated in the afternoon, Bloomberg reported that pharmaceutical sector mainstay Abbott Laboratories appears to be on the brink of acquiring Exact Sciences.

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...